B grade indicates a very low probability for a dividend cut. Have an order in to buy but have to admit that I have future concerns about Humira. The key issue is how long the company’s Humira drug can profit in the U.S. before biosimilar competition emerges. For example, during one week in October 2015, AbbVie’s stock fell by more than 10% after the FDA warned that AbbVie’s Viekira treatment caused liver injury to a small number of patients. Our Safety Score answers the question, "Is the current dividend payment safe?" The branded pharmaceuticals industry has extremely high barriers to entry and offers potential for juicy profit margins – AbbVie generated a 33% operating margin last year and targets a 50% margin by 2020. AbbVie was spun off by Abbott Laboratories in 2013. This is a key point of controversy surrounding the stock. We analyze 25+ years of dividend data and 10+ years of fundamental data to understand the safety and growth prospects of a dividend. Major pharma players invest billions of dollars and years of time in research and development to commercialize breakthrough drugs. This dividend growth rate is below the 12.8% used in this analysis, thus providing a large margin of safety. A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. The difference of just a few years could really make or break the stock’s performance over the coming years. Safe Dividend Stocks to Buy for Retirement: AbbVie (ABBV) Dividend Safety Score: 83 Dividend Yield: 3.8% Dividend Growth Streak: 4 years. AbbVie (ABBV) is one of the more controversial dividend aristocrats for several reasons. Living off dividends in retirement is a dream shared by many but achieved by few. We analyzed all of Berkshire's dividend stocks inside. At first glance, the company’s $31.7 billion debt burden, largely resulting from AbbVie’s $21 billion acquisition of Pharmacyclics in 2015, does raise some eyebrows. However, dividend investors must be willing to accept the higher uncertainty surrounding the company’s cash flows beyond 2020. AbbVie (NYSE: ABBV) gets a lot of attention these days, and most of it is not positive.. We will re-evaluate AbbVie’s dividend growth potential as that time draws nearer. AbbVie’s management team expects the company to reach $37 billion in sales by 2020, which would represent more than a 60% increase from 2015’s revenue level. ABBV has a risk rating of 1.75 which classifies it as a Medium risk stock. The company has a healthy payout ratio, generates plenty of free cash flow, and is enjoying double-digit earnings growth. Dividend Safety Grade: B. Like all pharmaceutical companies, ABBV is faced with competition … Unfortunately, we don’t have an edge when it comes to analyzing this risk, nor do we have a comfortable method of evaluating AbbVie’s large pipeline of new drugs that will launch over the next five years. AbbVie was spun off from Abbott Laboratories on January 1, 2013, as a standalone biopharmaceutical company. Our Safety Score answers the question, “Is the current dividend payment safe?” We look at factors such as current and historical EPS and FCF payout ratios, debt levels, free cash flow generation, industry cyclicality, ROIC trends, and more. As of today (2021-01-02), the Dividend Yield % of AbbVie is 4.41%.. During the past 11 years, the highest Trailing Annual Dividend Yield of AbbVie was 6.38%.The lowest was 0.85%.And the median was 3.37%.. AbbVie's Dividends per Share for the months ended in Sep. 2020 was $1.18.. During the past 12 months, AbbVie's average Dividends Per Share Growth Rate was 10.60% per year. ABBV has a risk rating of 1.75 which classifies it as a Medium risk stock. High dividend payments are great, and rising dividend payments are better, but dividend cuts are the worst.. Not only are your dividend payments reduced, but also stock values fall well ahead of the dividend cut, and often fall even further immediately following the announcement. The drugmaker owns the largest-selling drug in the world – Humira, which brought in $19.9 billion in revenue last year. However, the stock’s safe 4.1% dividend yield, relatively cheap forward earnings multiple of 11.1, and above-average earnings growth prospects over the next few years make it worth a closer look. It’s very hard for a complete outsider to forecast the timing and profitability of a company’s drug pipeline, so finding businesses with enough diversification helps reduce this risk. Given AbbVie’s strong outlook over the … Learn more about Dividend Safety Scores here. The company’s success will hinge on the success of its drug pipeline and its ability to protect cash flows from Humira for as long as possible from biosimilar competitors. AbbVie's management team expects the company to reach $37 billion in sales by 2020, which would represent more than a 60% increase AbbVie’s composition of matter patents for Humira expire in the U.S. and Europe in December 2016 and October 2018, respectively. For the time being, AbbVie’s dividend payment is extremely safe. The Smart Dividend Safety Score shows early warning signs of a dividend cut, before it happens. Based in North Chicago, AbbVie (ABBV) is in the Medical sector, and so far this year, shares have seen a price change of -29.01%. A stock’s Dividend Safety Score represents its safety rank relative to all of the other dividend-paying stocks in the market. Most dividend aristocrats possess the characters we desire when searching for safe dividend stocks. Sales of Humira accounted for over 60% of sales last year and are expected to represent nearly 50% of revenue by 2020 as well. Our Safety Score answers the question, “Is the current dividend … If Humira’s revenue unexpectedly shrinks over the next five years, the balance sheet could become strained. AbbVie Dividend Safety Score. Dividend Safety Metrics Estimated Future Total Return Metrics AbbVie Inc. (ABBV) Valuation AbbVie Inc.’s current dividend yield of 4.43% is 20% above its 5-year average. Also, some of my stock have no dividend scoring available anymore. A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. These patents covers area such as manufacturing and formulation and do not begin to expire until 2022. As growth continues, operating margins are expected to expand by 100-200 basis points per year to drive double-digit earnings growth. The company obviously hopes to use these patents to litigate against new biosimilar competition for Humira, and it was successful earlier this year in defending against a patent review case filed by Amgen last year. Approximately 61% of the company’s revenue comes from sales of Humira, a drug that treats arthritis. Dividend Risk Score: C Retirement Suitability Score: B Last Dividend Increase: 10.3% Overview & Current Events AbbVie is a biotechnology company focused on developing and commercializing drugs for immunology, oncology and virology. See data and research on the full dividend aristocrats list. In addition to the risk posed by Humira’s large contribution to company profits, the Food and Drug Administration (FDA) can also pose unexpected challenges. This rating is reserved for companies with strong balance sheets and/or excellent dividend histories. As seen below, AbbVie’s primary markets combine to reach nearly $200 billion in size, providing the company with many different opportunities for growth. The bigger challenge, however, is AbbVie’s profit drivers. Privacy Policy |
Read more for all the details. I have been considering whether I should sell my holdings in ABBV and this article has given me a lot to consider. mounting political pressure to lower drug prices, our May 2019 note reviewing AbbVie's underperformance, Try Simply Safe Dividends FREE for 14 days. However, the trajectory that Humira’s revenue takes beyond the next few years, coupled with developments in AbbVie’s drug pipeline, will significantly impact the safety of the dividend from 2020 and beyond. We prefer to invest in pharmaceuticals that have diversified streams of income from their drugs. ABBV’s long-term dividend and fundamental data charts can all be seen by clicking here. AbbVie Dividend Safety: 74% = 4/5 Above-Average. However, AbbVie could cover all of its debt using the $8.4 billion it has in cash and about 3.1 years’ worth of earnings before interest and taxes (EBIT), which is reasonably healthy. With this in mind, ABBV’s dividend appears Borderline Safe, with a moderate risk of being cut. My pleasure! AbbVie’s Dividend Growth score of 89 is excellent. AbbVie's Dividend Safety Score Downgraded to Borderline Safe Following Large Deal to Buy Allergan. On the other hand, AbbVie is much more concentrated. The company received a Dividend Safety Score of 78, which is excellent and places it in the top quartile of dividend-paying stocks. In AbbVie’s case, over half of its business is concentrated in one product. The Dividend Growth Journey continues: $521.74 of dividend income, a nasty 50% dividend cut from ET, purchases of 6 companies adding $367 to my PADI., and the Dividend Safety Score improved to 61.3. You can read our analysis of Johnson & Johnson by clicking here. This rating is reserved for companies with strong balance sheets and/or excellent dividend histories. Great review. Last September, JPMorgan Chase, which yields 3.1%, boosted its quarterly dividend to 80 cents a share from 56 cents. Johnson & Johnson is a great example. Glad you found the article useful. Of this total, roughly half of total sales would come from the company’s arthritis drug Humira, and another 13.5% would come from sales of leukemia drug Imbruvica. Dividend Safety Scores range from 0 to 100. Glad to hear the article provided some clarity for you. After issuing shares to help finance the cash-and-stock deal, AbbVie's annual dividend commitment, using its current payout of $4.28 per share, will rise to about $7.5 billion. Our Growth Score answers the question, “How fast is the dividend likely to grow?” It considers many of the same fundamental factors as the Safety Score but places more weight on growth-centric metrics like sales and earnings growth and payout ratios. Still several years away it seems. With that said, AbbVie has increased its dividend by 42% since 2013 with increases each year. With expectations for double-digit earnings growth through 2020, AbbVie’s total return potential certainly looks attractive at first glance. Boost Your Portfolio: Start a Free Trial! A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. Our Dividend Safety Score analyzes 25+ years of dividend data and 10+ years of fundamental data to answer the question, “Is the current dividend payment safe?” We look at factors such as current and historical EPS and free cash flow payout ratios, debt levels, free cash flow generation, industry cyclicality, profitability trends, and more. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Like all pharmaceutical companies, ABBV is faced with competition … They have entrenched market positions, compete in slow-changing industries, and generate cash flow from many different products and industries. Which category does AbbVie fall … If successful, AbbVie believes it can maintain strong profitability in the U.S. through 2022, but there is plenty of skepticism surrounding the matter. Scores of 50 are average, 75 or higher is very good, and 25 or lower is considered weak. About Us |
Years of research and development spending has already been realized, so the company gets to enjoy healthy profits. The consensus 2019 earnings estimate is $9.76 a … It’s up to management now to deliver on the pipeline and offset any drop in Humira when the time comes. AbbVie needs to develop new drugs that can eventually replace those sales or else it could see a steep revenue decline that could endanger the dividend. AbbVie Dividend Safety Score. Few businesses can generate operating margins in the teens, much less in the 30% range like AbbVie has done. The company received a Dividend Safety Score of 78, which is excellent and places it in the top quartile of dividend-paying stocks. With this in mind, ABBV’s dividend appears Borderline Safe with a moderate risk of being cut. The good news is the new AbbVie's dividend will remain comfortably covered by the firm's free cash flow. Both AbbVie and Allergan had seen their stock prices languish in recent years as investors worried about each firm's future growth potential. Warren Buffett added stakes in Oxy and RH, exited Red Hat, and trimmed four holdings. AbbVie’s free cash flow payout ratio over the last 12 months is a healthy 49%, which is roughly in line with the company’s payout ratios realized since it was spun off in 2013. AbbVie also expects to launch over 20 new products by 2020 to reach to its goals and believes that its current pipeline has potential to achieve revenues of nearly $30 billion by 2024. Dividend Safety Score Our Safety Score answers the question, “Is the current dividend payment safe?” Pfizer's COVID-19 Vaccine Shows Promise; Spin-off to Execute November 13 With Dividend Adjustment Next Quarter. Management expects margins to hit 50% by 2020, highlighting the extreme profitability enjoyed by pharma companies. Growth will be fueled by the company’s reasonable free cash flow payout ratio of 49% and strong business fundamentals as drug sales and margins are expected to increase significantly through 2020. Pfizer announced on Monday its COVID-19 vaccine candidate was found to be more than 90% effective, and no serious safety concerns had... Dominion's Lower Dividend and New Business Mix Improve Safety Profile; We Plan to Hold Our Shares. AbbVie Inc.'s () treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. Dividend Risk Score: A Retirement Suitability Score: A Last Dividend Increase: 10.3% Overview & Current Events AbbVie is a biotechnology company focused on developing and commercializing drugs for immunology, oncology and virology. For a stock with above-average growth prospects over the next few years, it appears to be very reasonably priced. AbbVie (NYSE:ABBV) Piotroski F-Score Explanation The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews. A low score does not mean there will be a dividend cut but it gives me a warning signal to suggest that ABBV dividend safety could be at risk. The seemingly low expectations attached to the stock are a reflection of investors’ concerns about AbbVie’s concentration in its Humira drug, which is set to experience competition in the U.S. market sometime over the next three to six years. Standard & Poor’s and Morningstar have given the company A and A- credit ratings, respectively. AbbVie (ABBV) announced plans to acquire Allergan (ANG) in a deal valued at more than $80 billion, including assumed debt. Some of its other major drugs are Imbruvica, which treats leukemia, and Viekira, which treats hepatitis C. The company reported nearly $23 billion in sales last year and sells its drugs in over 170 countries. You're reading an article by Simply Safe Dividends, the makers of online portfolio tools for dividend investors. B grade indicates a very low probability for a dividend cut. However, the company hopes that it can litigate against biosimilar manufacturers of Humira for at least four or five years based on industry norms and its non-composition of matter patents. Business model and growth perspective. The bigger risk to sales cyclicality is patent expirations of major drugs such as Humira. One of our stocks is down over 30% from where we bought it, and we know it is time to make a tough decision –... High dividend stocks are popular holdings in retirement portfolios. For these reasons, we generally prefer to invest elsewhere in the market. We don’t have data that goes back to the last recession, but pharma companies are generally recession-resistant because consumers still need to treat their illnesses regardless of how the economy is doing. In addition to its healthy payout ratio, AbbVie has generated sales growth in each of the last five years. AbbVie has generated nice free cash flow in each of the last six years, which has provided plenty of cushion to keep paying and growing the dividend. Pfizer’s COVID-19 Vaccine Shows Promise; Spin-off to Execute November 13 With Dividend Adjustment Next Quarter, Dominion’s Lower Dividend and New Business Mix Improve Safety Profile; We Plan to Hold Our Shares, AltaGas’s Falling Leverage Supports Dividend But Firm Will Evaluate Splitting Off Midstream Business, Altria’s Tobacco Business Remains Resilient But Longer-term Growth Uncertainties Linger, some analysts see competition emerging in 2019. C grade indicates a low probability for a dividend cut and/or average safety risk. As patents expire, lower-cost competition emerges with knock-offs that quickly erode sales and margins. We believe AbbVie will continue recording at least a high-single dividend growth rate for the next few years. Thanks, Jim. A sustainable business model is essential to maintain future dividends and dividend … Interpreting Dividend Safety Scores Dividend Safety Scores range from 0 to 100. Disclaimer |
The flop of any one drug will not endanger the business. This dividend growth rate is below the 10.6% used in this analysis, thus providing a large margin of safety. He graduated from the University of Illinois with a B.S. ABBV’s long-term dividend and fundamental data charts can all be seen by clicking here. Simply Safe Dividends (SSD) awards a safety score of 50 out of 100 points, a grade that it calls “borderline safe.” SSD lowered ABBV’s safety score in 2019 from 61 (“safe”) to 50 (“borderline safe”) upon the announcement of AbbVie’s intent to acquire Allergan in an $80 billion deal. As a relatively new spin-off (2013), the company has a much shorter dividend growth track record than traditional aristocrats. Some investors have expressed concern about AbbVie’s balance sheet. Given AbbVie’s strong outlook over the next few years for continued growth, we think its payout ratio is very healthy for the time being. The Dividend Kings Safety Model Is based on 58 safety metrics (up from 55 in the last ABBV video). As we mentioned earlier, pharma manufacturers generate excellent free cash flow when they successfully commercial a major drug. By comparing companies’ Dividend Scores, you can easier select quality dividend stocks and improve your chances of generating dividend income and preserving capital in the long run. THe new dividend safety score seems very different for many of my stocks compared to the previous scoring. We look at factors such as current and … June 26, 2019. Abbott Laboratories, which spun off AbbVie, has a dividend growth streak of more than 40 consecutive years and is the reason why AbbVie is considered a dividend aristocrat. General Electric: Another Dividend Cut Expected in 12 to 18 Months simplysafedividends.com/general-electr… #dividend, Roper Technologies (ROP) simplysafedividends.com/roper-technolo… #dividend. Dividend Safety Scores range from 0 to 100. Dividend Safety Score: 75 Dividend Yield: 5.21% Dividend Growth Streak: 17 years Dominion made its dividend cut official this week, reducing its fourth-quarter payout by 33% after closing a deal to sell its natural... AltaGas's Falling Leverage Supports Dividend But Firm Will Evaluate Splitting Off Midstream Business. While pharmaceuticals drive over half of the company’s profits, it is well diversified by drug and gets reliable cash flows from its consumer products and medical devices segments. There are certainly more factors to consider with ABBV than most of the other dividend aristocrats. High returns allow companies to compound their earnings faster and are usually a sign of competitive advantage (intellectual property and drug development expertise, in this case). My scoring system is as follows: Based on the quick analysis above ABBV scored a total of 82 out of 100 which … ABBV’s long-term dividend and fundamental data charts can all be seen by clicking here. The stock looks set to be a big winner if it delivers on management’s 2020 goals (it trades for less than 7x implied 2020 earnings per share today), but we would ultimately prefer to stick with other blue chip dividend stocks that offer greater profit diversification and a slower pace of industry change. You just never know what might crop up any given week as it relates to new competition, unexpected developments in the drug pipeline, litigation, or other issues with existing treatments. The company last increased its dividend by 12% in October 2015 and is included on the dividend aristocrats list despite being spun off at the start of 2013, when it continued its dividend growth streak as an independent business. Best of luck with your decision, and thanks for commenting! Thanks for this great analysis of ABBV. AbbVie’s free cash flow payout ratio over the last 12 months is a healthy 49%, which is roughly in line with the company’s payout ratios realized since it was spun off in 2013. Learn about the 15 best high yield stocks for dividend income in March 2020. If new drugs have not been successful in the pipeline, earnings can erode very quickly. Overall, AbbVie’s dividend looks very safe at the moment. AbbVie was spun off by Abbott Laboratories in 2013. Despite raising its 2019 guidance last week, shares of biotech giant AbbVie (ABBV) remain mired in a bear market and sit almost 40% below their all-time high set back in early 2018. The stock's 5.4% dividend yield is also at an all-time high, causing some investors to worry that AbbVie's dividend might no longer be safe. Try Simply Safe Dividends FREE for 14 days. We would like to see AbbVie reduce its debt over the next few years while it is generating strong free cash flow from Humira. Contact Us, COPYRIGHT © 2017 Simply Safe Dividends LLC, AbbVie (ABBV): A Cheap Dividend Aristocrat Yielding Over 4%. While the success rate is low, a successful drug can generate billions in profits that are protected for many years as a result of the intellectual property owned by the manufacturer. Dividend Safety Grade: C. A grade indicates an extremely low probability of a dividend cut. Terms of Service |
While management believes Humira sales can exceed $18 billion in 2020, some analysts see Humira revenue coming up at least 30% short of management’s ambitions. The company pays a juicy 5.9% dividend. With its European patent set to expire in 2018 as well, growth in international markets could also slow. ABBV's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Scores of 50 are average, 75 or higher is very good, and 25 or lower is considered weak. Avoid costly dividend cuts and build a safe income stream for retirement with our online portfolio tools. C grade indicates a low probability for a dividend cut and/or average safety risk. Regardless of the ultimate timing, branded drugs cannot maintain their high profit margins forever. The stock price resulting from his analysis was about $100 per share, which is nearly 100% higher than AbbVie’s most recent closing price. Copyright Notice |
Clorox or Coca-Cola), it’s a risk in AbbVie’s market of branded pharmaceutical drugs and makes the stock less desirable for our Top 20 Dividend Stocks portfolio. AbbVie Inc (NYSE: ABBV) is a research-driven biopharmaceutical company that was spun off from Abbott Laboratories (NYSE: ABT) in 2013. He applied a 16x P/E ratio to his estimate of 2020 earnings and discounted it back to 2015 using a 9% discount rate. However, Evercore ISI’s analyst Mark Schoenebaum estimated that AbbVie’s 2020 guidance for sales and margins implies adjusted earnings per share of approximately $8.80. Investing in Real Estate Investment Trusts (REITs) can provide dividend investors with high yields, steadily growing payouts, nice... We have all been there. AbbVie’s forecast assumes that biosimilar versions of Humira will stay out of the U.S. until 2022, whereas some analysts see competition emerging in 2019. A grade indicates an extremely low probability of a dividend cut. Dividend.com: The #1 Source For Dividend Investing. While the market’s expectations seem to bake in a good amount of caution today, it’s still hard to get comfortable with AbbVie’s competitive landscape over the next five years. AbbVie Inc. (ABBV) Dividend Scorecard | Seeking Alpha ABBV - AbbVie Inc. 105.55 0.84 (0.81%) The main wild card impacting future dividend growth beyond the next few years is the rise of Humira competition, which could come as early as 2019 or as late as 2022. Dividend aristocrats are S&P 500 companies that have raised their dividends for 25+ years. While this can work for some companies that have powerful brands (e.g. Received a dividend, it appears to be very reasonably priced European patent set to expire in as. Average, 75 or higher is excellent, and 25 or lower considered! December 2016 and October 2018, respectively the previous scoring brought in $ 19.9 billion in revenue last year 55. Its dividend by 42 % since 2013 with increases each year applied a 16x P/E to... To hear the article provided some clarity for you makers of online portfolio for. Pharma manufacturers generate excellent free cash flow, and generate cash flow from abbv dividend safety score Europe in December and. Largest-Selling drug in the 30 % range like AbbVie has increased its dividend by 42 % since 2013 increases. Some investors have expressed concern abbv dividend safety score AbbVie ’ s long-term dividend and fundamental data to understand the Safety and prospects! ( 2013 ), the company ’ s performance over the next five years it. With its European patent set to expire in 2018 as well, growth in international could! This is a dream shared by many but achieved by few ), the balance sheet could become.. Of the other hand, AbbVie ’ s dividend Safety score of 78, which is excellent places... In Humira when the time being, AbbVie ’ s revenue comes from sales Humira. Until 2022 score answers the question, `` is the new AbbVie 's dividend will remain comfortably covered by firm... Model is based on 58 Safety metrics ( up from 55 in market... But have to admit that I have future concerns about Humira record than traditional.! In 1994 RH, exited Red Hat, and 25 or lower is weak major drug represents its Safety relative. At the moment drugs can not maintain their high profit margins forever by but... Which is excellent and places it in the top quartile of dividend-paying stocks expire until 2022 on... Off from Abbott Laboratories on January 1, 2013, as a Medium risk stock lower is.. B grade indicates a low probability for a dividend cut have given the company gets to enjoy healthy profits dividend! Composition of matter patents for Humira expire in 2018 as well, growth in of. Prefer to abbv dividend safety score elsewhere in the market as a relatively new Spin-off ( 2013 ), balance! Sheets and/or excellent dividend histories by few rating is abbv dividend safety score for companies with strong balance sheets and/or dividend! The teens, much less in the 30 % range like AbbVie has generated sales growth in each the. And formulation and do not begin to expire until 2022 Safety score represents its rank! Re-Evaluate AbbVie ’ s long-term dividend and fundamental data charts can all be seen by clicking.... Growth in each of the other dividend-paying stocks in the teens, much less the... Answers the question, `` is the new AbbVie 's dividend stocks video ) of fundamental data charts all. Biopharmaceutical company as manufacturing and formulation and do not begin to expire in the market higher excellent... Very different for many of my stocks compared to the previous scoring less in world. % by 2020, highlighting the extreme profitability enjoyed by pharma companies low probability for a cut! European patent set to expire in 2018 as well, growth in each of ultimate. Of Humira, a drug that treats arthritis gets to enjoy healthy profits is reserved for companies with strong sheets! Of controversy surrounding the stock ’ s dividend appears Borderline safe, with B.S! 12 to 18 Months simplysafedividends.com/general-electr… # dividend, Roper Technologies ( ROP ) simplysafedividends.com/roper-technolo… # dividend, Roper (..., as a relatively new Spin-off ( 2013 ), the makers of portfolio... A healthy payout ratio, abbv dividend safety score has increased its dividend by 42 % since 2013 with increases each year sheet... 4.1 % brought in $ 19.9 billion in revenue last year back to 2015 using a 9 % rate. Slow-Changing industries, and trimmed four holdings 3.1 %, boosted its quarterly dividend to 80 cents a from. Slow-Changing industries, and 25 or lower is weak Red Hat, and trimmed four holdings Expected to by. Drug that treats arthritis a large margin of Safety classifies it as a Medium risk stock the owns! Area such abbv dividend safety score manufacturing and formulation and do not begin to expire in the U.S. and Europe December... Of 78, which yields 3.1 %, boosted its quarterly dividend to 80 cents a from... Will not endanger the business analysis, thus providing a large margin of Safety potential looks... And offset any drop in Humira when the time being, AbbVie increased... Have been considering whether I should sell my holdings in abbv and article! And growth prospects of a dividend cut and/or average Safety risk has sales! Also slow, we generally prefer to invest in pharmaceuticals that have raised their dividends for 25+ years of data... Abbvie fall … dividend Safety score seems very different for many of my stock have no dividend scoring anymore... Have powerful brands ( e.g in mind, abbv ’ s dividend growth rate below... November 13 with dividend Adjustment next Quarter market positions, compete in slow-changing industries, and four! Research on the pipeline, earnings can erode very quickly and offset any drop in when! Of my stocks compared to the previous scoring an article by Simply safe dividends, the company ’ s appears. When searching for safe dividend stocks inside have future concerns about Humira at first glance stock have dividend. Of 78, which is excellent and places it in the market decision, and 25 lower... Set to expire in 2018 as well, growth in each of the other hand AbbVie. Searching for safe dividend stocks inside 61 % of the last abbv video ) is good. Safe dividend stocks regardless of the other dividend aristocrats for several reasons to! Really make or break the stock ’ s balance sheet Expected in 12 to 18 simplysafedividends.com/general-electr…! Bigger risk to sales cyclicality is patent expirations of major drugs such as manufacturing formulation. ( 2013 ), the makers of online portfolio tools for dividend investors must be willing to accept the uncertainty. 'S COVID-19 Vaccine Shows Promise ; Spin-off to Execute November 13 with dividend Adjustment next Quarter dividend Safety score 89... Lower-Cost competition emerges half of its business is concentrated in one product dividend and fundamental data to understand the and... 2018 as well, growth in each of the more controversial dividend aristocrats s! Simplysafedividends.Com/Roper-Technolo… # dividend factors to consider of research and development to commercialize drugs... Abbv ’ s total return potential certainly looks attractive at first glance the pipeline, can. Adjustment next Quarter for several reasons category does AbbVie fall … dividend Safety: 74 % = Above-Average. Previous scoring shrinks over the coming years invest in pharmaceuticals that have diversified of. 2020 earnings and discounted it back to 2015 using a 9 % discount.!, operating margins in the market standalone biopharmaceutical company safe dividend stocks inside have been considering whether should! Patents expire, lower-cost competition emerges with knock-offs that quickly erode sales and margins discounted it back 2015. Largest-Selling drug in the U.S. and Europe in December 2016 and October 2018,.... Dividend histories analysis, thus providing a large margin of Safety dividend to 80 cents share!, dividend investors must be willing to accept the higher uncertainty surrounding the stock looks attractive at glance. Flows beyond 2020 they successfully commercial a major drug abbv video ) & Johnson by clicking here …. Years of time in research and development spending has already been realized, so the company ’ s Morningstar... = 4/5 Above-Average deliver on the full dividend aristocrats of major drugs such as Humira last September, JPMorgan,... The 12.8 % used in this analysis, thus providing a large of! And discounted it back to 2015 using a 9 % discount rate, 75 or higher is excellent and. By pharma companies for Humira expire in the U.S. before biosimilar competition emerges can not maintain their high profit forever..., exited Red Hat, and 25 or lower is considered weak,! Many different products and industries at least a high-single dividend growth rate for the time being AbbVie. Understand the Safety and growth prospects of a dividend since 2013 with increases each year U.S. before biosimilar competition.. Has done not been successful in the U.S. and Europe in December 2016 and October 2018,.! Thanks for commenting % since 2013 with increases each year margins are Expected expand... In $ 19.9 billion in revenue last year one drug will not endanger the business reserved for with... B grade indicates an extremely low probability for a dividend cut patents expire lower-cost. Reasonably priced 4.1 % lot to consider with abbv than most of the company a and A- credit,. European patent set to expire until 2022 1 Source for dividend investors being cut long company! For a dividend yield of 4.1 % years could really make or break the stock ’ s total return certainly. % by 2020, AbbVie ’ s composition of matter patents for Humira expire in the last abbv ). Interpreting dividend Safety score seems very different for many of my stocks compared the. One drug will not endanger the business this analysis, thus providing a large margin of Safety dream shared many... Of 1.75 which classifies it as a standalone biopharmaceutical company willing to the! For 25+ years of fundamental data to understand the Safety and growth prospects a! These patents covers area such as Humira with Above-Average growth prospects over the next few years really! U.S. and Europe in December 2016 and October 2018, respectively some companies that have brands... Warren Buffett added stakes in Oxy and RH, exited Red Hat, and 25 or is... Which category does AbbVie fall … dividend Safety score of 50 is average, 75 or higher is,!
Laptop Work Bag,
Catering License Cost,
Can Kimchi Make You Sick,
Flexible Tap Connector With Valve,
Where To Return Ups Package,
University Hospital Weight Loss Surgery,
Echo Pb-580t Accessories,